C-CAR168, a Novel Bispecific Anti-CD20/BCMA CAR-T Therapy, Selected as Late-Breaking Abstract at ACR Convergence 2025

Oct 21, 2025 07:20 CST Updated 07:20

AbelZeta

Developer of Immune Cell and Stem Cell Therapy Products

October 21, 2025

eMedClub News

Shanghai, China, Maryland, USA, October 21, 2025 — Cellular Biomedicine Group (Shanghai) Ltd("Cellular Biomedicine Group" or "Company")Is a global clinical-stage biopharmaceutical company focused on discovering and developing innovative and proprietary cell therapy products. The company announced today,The first-in-human Phase I trial of its core product, C-CAR168, in patients with refractory autoimmune diseases（NCT06249438）Clinical data has been accepted by the 2025 American College of Rheumatology（ACR）Convergence Annual Meeting Selected as a Breakthrough Abstract and Will Be Presented as a Poster During the Conference. C-CAR168 is an autologous bispecific chimeric antigen receptor T cell.（CAR-T）Therapy targeting CD20 and BCMA aims to simultaneously eliminate antibody-producing plasma cells and their B-cell precursors, thereby achieving immune system reconstitution.This mechanism provides new possibilities for the treatment of various refractory autoimmune diseases. The American College of Rheumatology Annual Meeting is the most authoritative and influential academic event in the global rheumatology field, gathering the latest research findings, clinical advancements, and expert consensus.The conference will be held at the McCormick Place Convention Center in Chicago, Illinois, from October 24 to 29, 2025.

Details of the latest breakthrough poster presentation are as follows

- Presentation Type: Poster

- Category: Latest Breakthrough Poster

- Abstract ID: 2211304

- Abstract Title:Anti-CD20/BCMA Bispecific CAR-T Cell Therapy Promotes Immune Reset and Sustained Drug-Free Remission in Patients with Refractory Autoimmune Diseases

- Poster presentation time: October 26(Sunday)--October 28(Tuesday)

- Poster presentation time: October 28(Tuesday)10:30 AM – 12:30 PM Central Time (US)

- Poster Presentation Author: Professor Nan Shen

- Location: McCormick Exhibition Center F1 Hall

AboutCellular Biomedicine Group

Cellular Biomedicine Group is a clinical-stage global biopharmaceutical company with innovation centers in Maryland, USA, and Shanghai, China. It focuses on developing innovative cell therapy products and is committed to combating malignant hematological tumors, solid tumors, inflammation, and immune diseases through personalized treatments that harness the body's own immune system. The company operates manufacturing facilities compliant with Good Manufacturing Practice (GMP) standards within each of its innovation centers.（GMP）The production base is used to promote product research and development and early clinical research, with a pipeline covering CAR-T therapy.

Disclaimer

The statements in this communication regarding plans, strategies, specific activities, and other descriptions of non-historical facts are forward-looking statements. Forward-looking information inherently involves certain risks and uncertainties, which are influenced by various factors that may cause actual results to differ materially from current expectations. These forward-looking statements are based on present views and management’s expectations, and are subject to factors beyond the control of AbelZeta Pharma, Inc.("AbelZeta" or "Company")Significant risks and uncertainties within the scope of control. In light of these uncertainties, you should not place undue reliance on such forward-looking statements, which represent views as of the date of issuance of this article. Unless otherwise required by law, AbelZeta has no obligation and expressly disclaims any duty to update, modify, or otherwise revise any forward-looking statements made from time to time, whether made in writing or orally, regardless of whether such revisions arise due to new information, future events, or other reasons.

Statement and Copyright Notice

Disclaimer: This article aims to convey industry development information and explore the frontier progress of biomedicine. The content of the article represents the author's viewpoint, and does not represent the position of EMedClub, nor does it constitute any value judgment, investment advice, or medical guidance. If needed, please consult a professional for investment or visit a正规 hospital for medical advice.

Copyright Statement:Welcome to share the article on your personal Moments. Unauthorized reproduction by media or organizations in any form to other platforms is prohibited. For reprint, please leave a message under the article to obtain authorization.

DianDian "Share”、“Like" and "In View", charge me up a bit~"